Sodium-glucose cotransporter-2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4is) are glucose-lowering agents that have been shown to reduce cardiovascular risk in T2DM patients [36]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.